ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2023
Differential utilization of Impella devices, extracorporeal membrane oxygenation, and combined therapies as escalation and de-escalation strategies.
Article in European heart journal supplements : journal of the European Society of Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 13 citations in OpenAlex.
- Transaxillar Impella Implantation: Learning Curve Analysis and the Role of Mentorship in Accelerating Proficiency.Journal of clinical medicine · 2026Article
- Percutaneous Interventions for Heart Failure in Congenital Heart Disease.Current cardiology reports · 2026Review
- Case Report: Extracorporeal membrane oxygenation in acute coronary syndrome: a rare case of massive left ventricular thrombus.Frontiers in cardiovascular medicine · 2026Article
- Phase-Specific Hemodynamic Criteria and Outcomes in Patients With Cardiogenic Shock Receiving Percutaneous Ventricular Assist Devices.Journal of the American Heart Association · 2025Article
- Optimizing outcomes in heart transplantation: multidisciplinary Heart Teams and mechanical circulatory support for primary graft dysfunction.European heart journal supplements : journal of the European Society of Cardiology · 2025Article
- State of the art treatment with Impella® in cardiac surgery in Austria.Wiener klinische Wochenschrift · 2024Article
- Percutaneous Mechanical Circulatory Support in Acute Heart Failure Complicated with Cardiogenic Shock.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiogenic shock (CS) is a life-threatening condition characterized by a state of inadequate systemic tissue perfusion caused by cardiac dysfunction. When to implement, change, or remove the use of a temporary mechanical circulatory support (tMCS) in patients with CS is dependent on the aetiology and severity. Here, patient scenarios underlying the need to escalate, de-escalate, wean, or bridge from tMCS devices are taken into consideration by interdisciplinary heart failure and CS teams. This includes a comprehensive review of and focus on the rationale for specific device escalation and de-escalation strategies, device selection, and general management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.